US FDA approves nivolumab and ipilimumab as first-line treatment of patients with metastatic non-small cell lung cancer whose tumours express PD-L1≥1%

This approval is based on part 1a of phase 3 CheckMate -227 trial (n=793) in which the combination demonstrated superior overall survival vs. chemotherapy (HR 0.79; 95% CI, 0.67 to 0.94; p=0.0066) regardless of tumour histology with a minimum follow up of 29.3 months.


Biospace Inc.